8/12/2019 Diabetic Nephropathy Dr Rahul
1/57
DIABETIC NEPHROPATHY
Dr. P. Rahul
Nephrologist
8/12/2019 Diabetic Nephropathy Dr Rahul
2/57
INTRODUCTION
Microvascular complication
Occurs in upto 40% of diabetes patients
Emerging as a leading cause of ESRD in India Mortality of ESRD patients with Diabetes Mellitus is higher
than in ESRD patients without Diabetes
However all diabetic patients with ESRD do not have DN asunderlying cause of ESRD.
8/12/2019 Diabetic Nephropathy Dr Rahul
3/57
EPIDEMIOLOGY - DIABETES
Number of diabetics world wide: 171 million.
By 2030 - 334 million.
USA - 8%
Europe - 7%
India - 12-15% (Urban)
Type I ~ 10%
Type II > 90%
8/12/2019 Diabetic Nephropathy Dr Rahul
4/57
EPIDEMIOLOGY
General incidence of Diabetic Nephropathy:
30-40 % of patients with Type I DM
25-40 % of patients with Type II DM
20 - 30 % of Type I DMProgress to ESRD
1020 % of Type II DMProgress to ESRD
> 30 % of all chronic renal failure patients have Diabetic
Nephropathy
Diabetic Kidney 2007
8/12/2019 Diabetic Nephropathy Dr Rahul
5/57
EPIDEMIOLOGY
In Type 1 DM with Microalbuminuria:
3080 % develop albuminuria in 10-15 yrs
50-78% develop ESRD in 10-18 yrs
In Type 2 DM :
8-10% have microalbuminuria at diagnosis
20-40% develop albuminuria in 10-15 yrs
20% progress to ESRD in 10-18 yrs
Diabetic Kidney 2007
8/12/2019 Diabetic Nephropathy Dr Rahul
6/57
Genetic Susceptibility
Likelihood of developing DN is markedly increased in patients
with a diabetic sibling or parent who has diabetic nephropathy.
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
7/57
Age
Increasing age, along with increasing duration of diabetes,
was associated with increased risk for developing
albuminuria.
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
8/57
Blood Pressure
Association between the subsequent development of
nephropathy and higher systemic pressures.
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
9/57
Glycemic Control
Diabetic nephropathy is more likely to develop in patients with
worse glycemic control (higher HbA1c levels).
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
10/57
Race
Increased incidence in African-Americans, Pima Indians,
Asians
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
11/57
Obesity
Associated with an increased risk of chronic kidney disease
among patients with diabetes.
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
12/57
Smoking
Associated with increases in albuminuria and the risk of end-
stage renal disease and of decreased survival once dialysis is
begun.
RISK FACTORS FOR DN
8/12/2019 Diabetic Nephropathy Dr Rahul
13/57
NATURAL HISTORY
DN develops after a well defined time period and is usually
associated with retinopathy
DN is characterised by certain well defined stages and presents with
proteinuria , hypertension and renal failure.
All renal disease in a diabetic is not Diabetic Nephropathy
8/12/2019 Diabetic Nephropathy Dr Rahul
14/57
TIME TO ONSET
20 to 30 percent will have microalbuminuria in 15 years
Less than half of these patients will progress to overt
nephropathy.
Onset of overt nephropathy is typically between 10 and 15
years after the onset of the disease.
Those patients who have no proteinuria after 20 to 25 years
have a risk of developing overt renal disease of only about 1
percent per year.
8/12/2019 Diabetic Nephropathy Dr Rahul
15/57
RELATION BETWEEN DIABETIC
NEPHROPATHY AND RETINOPATHY
Patients with nephropathy and type 1 diabetes almost always
have other signs of diabetic microvascular disease, such as
retinopathy and neuropathy
Relationship between diabetic nephropathy and retinopathy is
less predictable in type 2 diabetes
8/12/2019 Diabetic Nephropathy Dr Rahul
16/57
Type 2 diabetics with marked proteinuria and retinopathy most
likely have diabetic nephropathy, while those without
retinopathy have a high frequency of non-diabetic glomerular
disease
30 percent of type 2 diabetics with renal insufficiency have non-
diabetic renal disease
RELATION BETWEEN DIABETIC
NEPHROPATHY AND RETINOPATHY
8/12/2019 Diabetic Nephropathy Dr Rahul
17/57
2007 K/DOQI Guidelines for diabetes and chronic kidney
disease suggest that chronic kidney disease should be
attributed to diabetes in most patients with diabetes if
microalbuminuria and diabetic retinopathy are both present.
By comparison, other causes of CKD should be entertained if
diabetic retinopathy is absent
RELATION BETWEEN DIABETIC
NEPHROPATHY AND RETINOPATHY
8/12/2019 Diabetic Nephropathy Dr Rahul
18/57
Non Diabetic renal disease
suspected when.
No retinopathy
Absence of albuminuria
Rapid increase in serum creatinine.
Presence of active urinary sediment.
8/12/2019 Diabetic Nephropathy Dr Rahul
19/57
Stage Duration Features
I Hypertrophy < 2 yrs Nephromegaly, No laboratory
abnormalities, RPF
II Histological
abnormalities
> 2 yrs Initial morphological lesions :
GBM thickness, Mesangium
III Incipient
nephropathy
10-20
yrs
Microalbuminuia, GFR - N
Hypertension (50%)
IV Overtnephropathy
15-20yrs
Persistent proteinuria, HTN(70%), RPF & GFR
V End stage
renal disease
20-40
yrs
GFR < 10%
Hypertension (90%)
MOGENSENS STAGING
8/12/2019 Diabetic Nephropathy Dr Rahul
20/57
Stagingwell defined in Type 1 DM
In Type 2
15-30% patients can have Microalbuminuria at diagnosis
(Stage 3)
2-8 % can have Overt proteinuria at diagnosis (Stage 4)
8/12/2019 Diabetic Nephropathy Dr Rahul
21/57
SCREENINGWhen ?
Type 1 DM
Young patientsfrom puberty
Adults - 5 yrs after diagnosis Type 2 DM
At diagnosis
Yearly thereafter in both
8/12/2019 Diabetic Nephropathy Dr Rahul
22/57
How ?
Spot Urine albumin-creatinine ratio
24 hour urinegold standard Dipstick/Micral
8/12/2019 Diabetic Nephropathy Dr Rahul
23/57
ALBUMINTO-CREATININE RATIO
Calculation of albumin-to- creatinine ratio in an untimed urine
specimen.
A value above 30mg/g or 0.03mg/mg suggests that albumin
excretion is above 30mg/d and hence microalbuminuria is
probably present.
Almost 100% sensitivity for detection of microalbuminuria.
Preferred screening strategy for all diabetic patients.
8/12/2019 Diabetic Nephropathy Dr Rahul
24/57
MICROALBUMINURIA
Persistent albumin excretion between 30 and 300 mg/day (20
to 200 g/min) is called microalbuminuria
At least 2/3 samples positive for microalbuminuria in 6
months.
No e/o infection, hyperglycemia, no prior exertion.
8/12/2019 Diabetic Nephropathy Dr Rahul
25/57
Significance:
Type I DM:
Predicts overt nephropathy
Type II DM:
Predicts CV mortality
Predicts nephropathy
MICROALBUMINURIA
8/12/2019 Diabetic Nephropathy Dr Rahul
26/57
MICROALBUMINURIA AND GFR
Loss of renal function - defined as an estimated decrease in
GFR of more than 3.3 percent per yearoccurred in
9% of patients with normoalbuminuria
16% - regression of microalbuminuria.
32% - Stable microalbuminuria
68% - Progressive microalbuminuria
8/12/2019 Diabetic Nephropathy Dr Rahul
27/57
PROGRESSION TO
MACROALBUMINURIA
Albumin excretion above 300 mg/day (200 g/min) is
considered to represent macroalbuminuria
Rate of progression from microalbuminuria to
macroalbuminuria was 2.8 percent per year
Mean rate of loss of GFR in patients with macroalbuminuria
was 0.93 mL/min per month
8/12/2019 Diabetic Nephropathy Dr Rahul
28/57
M N GEMENT OF DN
Primaryprevention
Secondaryprevention
Tertiaryprevention
ESRDMADMOvert
nephropathy
Ref. Tobe SW et al. CMAJ 2002; 167(5): 499-503
8/12/2019 Diabetic Nephropathy Dr Rahul
29/57
LIFE STYLE MODIFICATION
Ideal body weight
Abstinence from alcohol
Cessation of smoking
Regular exercise
8/12/2019 Diabetic Nephropathy Dr Rahul
30/57
PRIMARY PREVENTION
Glycemic control
Strict glycemic control is recommended in all patients
because of its beneficial effects on microvascular
complications
8/12/2019 Diabetic Nephropathy Dr Rahul
31/57
L NDM RK TRI LS
Type I DM - DCCT
Type II DM - UKPDS
Tight glycemic control leads to significant decrease in retinopathy,
neuropathy and nephropathy and macrovascular complications
8/12/2019 Diabetic Nephropathy Dr Rahul
32/57
Adapted from Diabetes Care ,Jan 2007
Key concepts in setting glycemic goals:
A1C is the primary target for glycemic control
Ideal HbA1C < 7%
More stringent glycemic goals (i.e., a normal A1C,
8/12/2019 Diabetic Nephropathy Dr Rahul
33/57
Glycemic Control
Diet
Exercise
Insulin
Oral hypoglycemic agents
8/12/2019 Diabetic Nephropathy Dr Rahul
34/57
OHAs in CKD
8/12/2019 Diabetic Nephropathy Dr Rahul
35/57
OHA s in CKD
8/12/2019 Diabetic Nephropathy Dr Rahul
36/57
ACE INHIBITORS OR ARBS
Three randomized, placebo-controlled trials of 256 to 3326
patients with diabetes and normoalbuminuria (RASS,
EUCLID, DIRECT) showed no benefit from angiotensin
inhibition
There is no evidence that ACE inhibitors or ARBs are
effective for the primary prevention of microalbuminuria in
patients with diabetes who are normoalbuminuric and
normotensive.
8/12/2019 Diabetic Nephropathy Dr Rahul
37/57
SECONDARY PREVENTION
How to control proteinuria?
Dietary Management
0.6-0.8 g/kg protein day, normal (1-1.2 gm/kg) if on dialysis
High Biological value proteins
Vegetable protein better
Essential amino acids
Ketoanalogues of essential amino acids
8/12/2019 Diabetic Nephropathy Dr Rahul
38/57
Salt intake and proteinuria
high salt intake has been shown to blunt the antiproteinuric
effects of angiotensin inhibitors in patients with non-diabetic
kidney disease.
Salt restriction and/or diuretics enhance the effect of renin-
angiotensin blockade on proteinuria
Salt restriction to 70 meq/day has been found to enhance
the antiproteinuric effects of ARB in patients with type 2
diabetes
8/12/2019 Diabetic Nephropathy Dr Rahul
39/57
ACEI & ARBS
Beyond BP Control
Proteinuria
RAS
Growth factors
Free oxygen radicals
Antifibrotic role
Sodium absorption
8/12/2019 Diabetic Nephropathy Dr Rahul
40/57
ACE inhibitor plus ARB
The superiority of combination therapy with an ACE inhibitor
and an ARB compared to either therapy alone in decreasing
proteinuria has been established in both type 1 and type 2
diabetes
combination therapy with an ACE inhibitor and ARB is
associated with a higher incidence of adverse effects
8/12/2019 Diabetic Nephropathy Dr Rahul
41/57
ARB plus aliskiren
The first effective oral direct renin inhibitor
Aliskiren lowers blood pressure to a degree comparable to
most other agents
In the AVOID trial, aliskiren plus losartan was associated with
a significant 20 percent greater reduction in proteinuria
compared to losartan alone
8/12/2019 Diabetic Nephropathy Dr Rahul
42/57
Aldosterone antagonism
Aldosterone antagonists appear to reduce proteinuria when
used alone, and to have an additive effect on proteinuria
when used in combination with an ACE inhibitor or an ARB in
both type 1 and type 2 diabetes
Spironolactone, Eplerenone
8/12/2019 Diabetic Nephropathy Dr Rahul
43/57
Other antihypertensive drugs
Diltiazem and verapamil appear to be as consistently effective
as an ACE inhibitor or ARB in lowering protein excretion in
diabetic patients
8/12/2019 Diabetic Nephropathy Dr Rahul
44/57
Other agents
Pentoxifylline lowers proteinuria
8/12/2019 Diabetic Nephropathy Dr Rahul
45/57
Weight reduction
Marked decreases in proteinuria may be observed in obese
diabetics who lose weight.
8/12/2019 Diabetic Nephropathy Dr Rahul
46/57
HYPERTENSION AND
PROGRESSION
Transmission to glomerulusinitiation of sclerosis
DBP > 90 mm hgprogression twice as fast
MAP of 90almost normalizes rate of decline (2
ml/min/year)
In proteinuric hypertensiveseffects more marked
8/12/2019 Diabetic Nephropathy Dr Rahul
47/57
HYPERTENSION
1. Diet
2. Exercise
3. Drugsicsers
calcium antagonists
8/12/2019 Diabetic Nephropathy Dr Rahul
48/57
* Lowering BP by any drugbeneficial
ACEI
ARBs
Ca channel blockers
Blockers
Diuretics
8/12/2019 Diabetic Nephropathy Dr Rahul
49/57
HYPERLIPIDEMIA AND
PROGRESSION Dyslipidemia implicated in the pathogenesis of progression
lipids nephrotoxic.
Increase glomerular capillary pressure.
Mesangial changesstructural and functional (lipid peroxidation
of LDLfoam cells )
Lipoprotein thrombi in the glomerular capillaries
8/12/2019 Diabetic Nephropathy Dr Rahul
50/57
HYPERLIPIDEMIA TREATMENT
Diet
Exercise
Drugs
Statins
Fibrates
8/12/2019 Diabetic Nephropathy Dr Rahul
51/57
ANEMIA AND PROGRESSION
Enhances renal hypoxia
Stimulates release of profibrotic cytokines
Target Hb 12 g/dL
Erythropoietin therapy and correction of anemiamay slow CKD prog ress ion
8/12/2019 Diabetic Nephropathy Dr Rahul
52/57
RENAL REPLACEMENT THERAPY
Dialysis
Hemodialysis
Peritoneal Dialysis
Transplant
8/12/2019 Diabetic Nephropathy Dr Rahul
53/57
NEWER THERAPIES
Inhibition of TGF-beta (Monoclonal Antibodies to TGF-beta)
appears to ameliorate diabetic nephropathy in experimental
models of diabetes and in preliminary human studies.
Protein Kinase C Inhibitors: Ruboxistaurine
Antifibrotic agents: Tranilast
Endothelin antagonist: Bosentan
8/12/2019 Diabetic Nephropathy Dr Rahul
54/57
NEWER THERAPIES
PPAR-gamma agonists
thiazolidinediones (eg, pioglitazone and rosiglitazone) -
variety of beneficial effects in animal models of diabetic
nephropathy, such as reductions in fibrosis, mesangial cell
proliferation, and inflammation
reduce urinary albumin excretion at various stages of
nephropathy and reduce blood pressure
8/12/2019 Diabetic Nephropathy Dr Rahul
55/57
NEWER THERAPIES
Reduction of Advanced Glycation end products: ACE I & ARB
Metformin
Aminoguanidine (Pinagedine)
Pyridoxamine
Lipoic acid
Vitamin E
Benfotiamine
Monoclonal Ab to Amadori glycated albumin
8/12/2019 Diabetic Nephropathy Dr Rahul
56/57
SUMMARY
Diabetic renal disease reaching epidemic proportions
All renal disease in a diabetic not diabetic nephropathy
Early detection importantSpot urine test/MICRAL
Multi-pronged approach
Diet, Glycemic control, Blood pressure control, ACEI/ARBs
Renal replacement therapies are available but a poor substitute
for prevention
8/12/2019 Diabetic Nephropathy Dr Rahul
57/57
THANK YOU